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Involution is a process whereby the mammary gland undergoes extensive tissue 
remodelling involving exquisitely coordinated cell death, extracellular matrix 
degradation and adipose tissue regeneration following the weaning of offspring. These 
processes are mediated in part through Jak/Stat signalling pathways, which can be 
deregulated in breast cancer. Synthetic in vitro analogues of the breast could become 
important tools for studying tumorigenic processes, or as personalized drug discovery 
platforms and predictors of therapeutic response. Ideally, such models should support 
3D neo-tissue formation, so as to recapitulate physiological organ function, and be 
compatible with high-throughput screening methodologies. We have combined cell lines 
of epithelial, stromal and immunological origin within porous engineered collagen 
matrices, demonstrating 3D specific molecular signatures. Furthermore seeded cells 
form mammary-like branched tissues, with lobuloaveolar structures that undergo 
inducible involution phenotypes reminiscent of the native gland under 
hormonal/cytokine regulation. We confirm that autophagy is mediated within 
differentiated mammary epithelial cells in a Stat-dependent manner at early time points 
following the removal of a prolactin stimulus (H/WD). In addition, epithelial cells 
express markers of an M2 macrophage lineage under H/WD, a process that is 
attenuated with the introduction of the monocyte/macrophage cell line RAW 264.7. 
Thus, such 3D models are suitable platforms for studying cell-cell interactions and cell 




The heterogeneity of cancer and the variation in tumour cell sensitivity to therapeutic 
compounds between individuals is a known difficulty in delivering effective treatments. In 
vitro 3D tissue models are promising candidates for development into high-throughput 
screening tools with the potential to be formulated to an individual’s requirements through 
inclusion of biopsy material. We have developed a 3D model of the mammary gland, 
combining cells of epithelial and stromal origin within defined engineered environments that 
can be adapted to this task, and can be utilised also for studies of normal mammary gland 
development 1. 
 
The mammary gland is a dynamic organ that undergoes a highly orchestrated process of cell 
death and tissue remodelling, known as post-lactational involution following the weaning of 
offspring. Involution results in progressive loss of milk-producing epithelial tissue and ECM 
degradation together with re-emergence of the adipose compartment. These processes are 
governed at a tissue level by numerous factors including LIF and OSM, members of the IL-6 
family of cytokines that mediate gene expression primarily through members of the Stat 
family of transcription factors 2. Indeed studies of JAK/Stat signalling deregulation in breast 
cancer have identified Stat3 as an important oncogene that adopts a constitutive mode of 
action in tumorigenic cells 3. Furthermore, the microenvironment of the involuting gland is 
conducive to the development and metastatic progression of breast tumours 4 and has been 
linked to pregnancy-associated breast cancer 5,6. 
 
Involution is marked by two defined phases, the first of which is reversible and triggered by 
milk stasis in the gland whilst the second commences with the expression of matrix 
metalloproteases (MMPs) 7 at approximately 48hrs involution in vivo. Interestingly it is not 
until this later phase in which there is gross destruction and remodelling of glandular tissue 
that the activation of classical apoptosis mechanisms become apparent. Our laboratory has 
previously shown that not only is cell death abated and involution delayed with the 
conditional deletion of Stat3 8, but that involution precedes in the absence of executioner 
caspases and is accomplished by Stat3 controlled lysosomal-mediated programmed cell 
death9. Stat3 has been shown to regulate autophagy 10 in liver and in vitro, and first phase 
involution is accompanied by the induction of autophagy as determined by the appearance of 
LC3 puncta11. Moreover, involution is perturbed by ablation of the key regulator of autophagy 
Atg7. The link between Stat3 signalling and the control of autophagic mechanisms is 
particularly important considering that beclin1-mediated defective autophagy leads to 
increased tumorigenesis and increased p62, causing mitochondrial damage and the generation 
of reactive oxygen species12. 
 
Post-lactational involution is analogous to a wound healing response involving complex 
epithelial-stromal cell interactions, the activation of elements of both innate and adaptive 
immune systems and expression of inflammatory cytokines and proteinases. The 
interdependence of multiple tissue types is critical for coordinated tissue remodelling, for 
example the degradation of basement membrane is driven by protease production originating 
from the fibroblastic component of the tissue7. Likewise, tissue resident and infiltrating bone 
marrow derived macrophages have been implicated in both post-natal mammary 
developmental and tissue remodelling processes13,14. It is well established that a reduction in 
macrophage number leads to an impairment of ductal morphogenesis during pregnancy15 
while specific depletion in the involuting mammary gland leads to a reduction in both 
lysosomal-mediated and apoptotic cell death14. In addition mammary gland repopulating stem 
cells have a reduced ability to transplant in colony stimulating factor (CSF) depleted glands16.  
Involution is associated with the polarization of macrophages away from a pro-inflammatory 
(M1) phenotype to an alternatively activated (M2) state, a phenotypic switch prevalent in a 
number of regenerating tissues 17,18, and recent work by our laboratory confirms that this 
polarization is Stat3 dependent and occurs within an infiltrating macrophage population from 
day 3 of involution19.  
 
Recognising the potency of, and requirement for, more physiological mammary gland 
models, the susceptibility of the involuting gland to tumorigenesis and the wide-ranging role 
of Stat3 in multiple aspects of involution led us to adapt our pre-existing 3D mammary model 
to studies of involution. Here we report that our model system recapitulates many aspects of 
this process in vitro, displaying Stat3 mediated cell death mechanism and supporting the 
interaction of epithelial, adipocyte and immune cells consistent with the native gland. We 
anticipate that such models will become an important resource for studies of tumorigenesis 
and drug discovery in addition to basic biology.  
 
Results and Discussion 
Porous 3D collagen based scaffolds confer physiological relationships to seeded cells.  
 
Involution involves co-ordinated cell death and tissue degradation, so any synthetic model 
must firstly support 3D physiological tissue formation with associated lumenogenesis and 
epithelial polarity. We demonstrated previously that porous freeze-dried collagen scaffolds 
supported growth of the KIM-2 mammary epithelial cell line to form bi-layered polarised 
ducts and acini 1. We show here that formation of these structures is associated with 
expression of specific proteins only in 3D culture. We analysed protein expression in KIM-2 
cells grown for 96hrs on tissue culture plastic, 2D collagen films and 3D porous scaffolds 
(Fig1a). Collagen films and scaffolds were fabricated in the same batch to ensure both 2D and 
3D surfaces were biochemically constant. It was noted that the 32kDa form of aquaporin-5 
(AQP5), a water transport molecule expressed at the apical domain of various polar epithelial 
tissues 20, was solely expressed under 3D culture conditions as visualised by immunoblotting 
(Fig 1a).  This is likely to be the glycosylated form of AQP5 21,22 as opposed to the lower 
molecular species present in all three culture conditions, and indicates that the 3D culture 
environment of our system confers functionality to in vitro cultured epithelial cells. 
Glycosylation has been shown to be necessary for appropriate localization of aquaporin 
protein complexes to the plasma membrane of MDCK cells 23.  
 
Further experiments were conducted using the 3D freeze-dried, cross-linked 
collagen/hyaluronic acid scaffolds24 supporting a co-culture of 3T3-L1 differentiated 
adipocytes together with KIM-2 cells, on the basis of previous data suggesting their support 
for mammary organoid formation favouring an alveolar-like phenotype1. Model setup 
involved the sequential seeding of 3T3-L1 cells, differentiated with adipogenic 
supplementation for a total of 2 weeks, prior to the introduction of KIM-2 cells (Fig 1b). 
Scaffolds were inoculated with both cell types at an initial seeding density of 1x106 cells/mL. 
KIM-2 cells were allowed to establish in co-culture supplemented in maintenance media 
(+EGF 10ng/mL) for a further 3 days prior to lactogenic hormone differentiation with PRL, 
dexamethasone and insulin, for 2 weeks. At this stage KIM-2 cells formed 
intercommunicating, polar ductal and alveolar-like structures with multiple isolated and 
intercommunicating lumens that demonstrated apical expression of AQP5 and the tight 
junction marker ZO-1 (Fig 1c,d). AQP5 is strongly expressed in virgin ducts25, but only 
weakly in lactational alveoli26 and it is interesting to note varying expression levels between 
organoids in the present study, possibly indicating the presence of both alveolar-type and 
ductal-type organoids. These organoids were surrounded by basement membrane as 
demonstrated by the organization of laminin (Fig 1d) and fatty tissue as shown by perilipin 
staining (Fig 1e). 
 
KIM-2 cells undergo physiological involution-type signalling under 3T3-L1 co-culture 
conditions.  
 
Our scheme for inducing an in vitro involution phenotype exploits the dependency of 
differentiated KIM-2 cells for prolactin (PRL) mediated survival signalling. Firstly we 
confirmed whether KIM-2 organoids regulate Stat3 and Stat5 phosphorylation in the same 
manner as the native gland, namely the downregulation or steady up-regulation of pStat5 and 
pStat3 respectively by removing PRL from the culture media (H/WD)27. Considering the 
close association of fatty and epithelial tissues in our model, we explored whether Stat 
signalling profiles were altered in the presence of adipose, using the 3T3-L1 pre-adipocyte 
cell model in 2D trans-well cultures. The re-emergence of adipocytes is a feature of 
involuting tissue while lipid promotes IL-6/TNF mediated activation of Stat3 in hepatocytes28 
and its utilization by the epithelium has been shown to sensitize these cells to programmed 
cell death mechanisms29. 
 
In a similar manner to results previously demonstrated over shorter timescales30, our study 
clearly showed a steady accumulation of pStat3 under H/WD conditions over a 4 day time 
period, elevated from an initial baseline following 2 weeks lactogenic treatment (Involution 
day0) (Fig S1a). Stat3 is constitutively expressed, although not phosphorylated, in all culture 
conditions as observed in vivo. Additionally pStat3 activity was accompanied by increases in 
the active forms of the lysosomal enzymes cathepsins L and B as well as the lipidated form of 
LC3B, LC3B-II indicative of ongoing autophagy. In the trans-well co-culture model, KIM-2 
cells demonstrated a similar up-regulation of pStat3 regardless of 3T3-L1 differentiation 
status (Fig S1b). However, immunoblotting of cleaved caspase 3 (cc3) clearly showed a peak 
accumulation at 48hrs following H/WD, and this up-regulation was attenuated by the 
presence of adipose in a trans-well model. It is also interesting to note the loss of 
phosphorylated Akt during H/WD, a common survival pathway in many cell systems. Thus, 
important aspects of involution can be mimicked in our 3D culture model. 
 
Prolactin withdrawal results in KIM-2 organoid regression and Stat3-mediated cell death in 
the 3D model. 
 
An involution phenotype was induced by H/WD for a total of 96hrs duration in 3D 3T3-
L1/KIM-2 co-cultures. Additionally, a positive control for Stat3 mediated cell death, which 
occurs during involution, was provided by OSM treatment (25ng/mL) which activates Stat3 
in mammary epithelial cells in vitro and in vivo 30,9. OSM was applied for the duration of the 
96hr experimental involution period with media replenishment every 24hrs. Under conditions 
of H/WD, organoids underwent morphological changes becoming elongated and more 
discontinuous in nature (Fig 2a, d). Systematic image analysis (Fig 2b, c) demonstrated a 
reduction in total lumen area and lumen frequency accompanied by an increase in organoid 
aspect ratio (Fig 2d).  
 
Immunohistochemical analysis revealed clear cell shedding into lumina in a similar manner to 
the gland in vivo (Fig 3a) although a proportion of cells also shed into the stromal space. The 
presence of shed cells within a patent lumen was confirmed by dual staining of AQP-5 and 
MFGE8. MFGE8 (Milk fat globule-EGF-factor 8/lactadherin) is a milk glycoprotein which 
has a critical role in mammary gland re-modelling during involution as it facilitates clearance 
of apoptotic cells31. In a similar manner cleaved caspase 3 (cc3) positive cells were observed 
within lumina, but also in the wall of epithelial structures as well as in the stromal space. The 
presence of cc3+ cells in the stromal space may reflect cell anoikis during scaffold seeding, or 
organoid formation failure in a subpopulation of structures resulting in partial polarity and 
basement membrane coverage at the basal margin.  
 
The withdrawal or prolactin for a total of 96hr resulted in a progressive increase in 
phosphorylated Stat3 in the 3D coculture model, in a similar manner to 2D mono and co-
cultures (Fig 3b). This was accompanied by a loss in β-casein expression that was more rapid 
under conditions of forced activation of Stat3 by OSM treatment. Prolactin withdrawal also 
resulted in increased pro and active forms of Cathepsin L by 96hrs, in addition to cc3. Despite 
the clear induction of cell death mediators, it is interesting to note that there was no associated 
loss in E-cadherin, possibly indicating the retention of ductal-type epithelial tissue with 
elongated morphologies. 
 
MMPs have an important role in mammary gland development and involution 32,33. An 
analysis of gene expression in a range of MMPs (Fig S2) demonstrated that both MMP3 and 
MMP9 were up-regulated following 96hr H/WD compared to mRNA abundance at 12days 
lactogenic differentiation. Additionally the expression of both of these genes was dependant 
upon co-culture status, with MMP-3 more strongly expressed in the absence of 3T3-L1 cells 
and a reciprocal expression profile for MMP-9.  The regulation of MMPs during mammary 
involution has been demonstrated in previous studies 30 where large increases in gene 
expression for MMP-2,3 and 9 have been evident by 72 hrs involution 33. 
 
We investigated cell death indicators further by scoring E-cadherin positive (ECAD+) cells 
for the apoptotic marker cc3, or p62 (sequestosome-1), an important molecule involved in 
recognising polyubiquitinated, aggregated and misfolded cargo proteins for incorporation into 
autophagic vesicles for trafficking to the lysosome and clearance in autophagolysosomes34. 
The 96hr involution timecourse did not result in any significant fluctuation in the number of 
cc3+ apoptotic cells per ECAD+ organoid, although an increasing trend was evident over the 
96hr period that was independent of OSM treatment (Fig 3c). In order to assess whether 
apoptosis could be induced in this model, we withdrew serum in the presence of lactogenic 
hormones and observed an over 2-fold increase in the number of cc3 positive cells (Fig S3).  
 
 
In contrast, an analysis of autophagic flux revealed an increased cytoplasmic level of p62+ 
puncta in ECAD+ cells under H/WD at both 24hr and 96hrs (p<0.05) (Fig 3d). This was 
further increased by the application of OSM, implicating Stat3 signalling in either modulating 
the rate of autophagic flux or in the resolution of autophagy. It is interesting to note the 
transient increase in p62+ expression at 24hrs followed by a pronounced decay, with levels 
returning to baseline values by 96hrs. This is against a background of an increasing lysosomal 
compartment, as measured by western blot for LAMP-2 (Fig3b). These data could indicate 
biochemical adaptation to an initial stimulus of H/WD +/- OSM treatment, particularly 
considering the observed increase (H/WD) or amplification (H/WD + OSM) in pStat3 signal. 
 
We explored these responses further by disrupting autophagosome and lysosome fusion35 by 
treating 24hr H/WD +/- OSM samples with the V0ATPase inhibitor Bafilomycin A1 (Baf). 
Optimal Bafilomycin concentration was determined previously by staining KIM-2 cells with 
LysoTracker ® Red dye and noting the minimal concentration required to inhibit acidification 
of the lysosomal compartment (50nM) (Fig S4). Bafilomycinin treatment for 5hrs resulted in 
a notable increase in the frequency of p62 puncta, an effect that was amplified in the presence 
of OSM (Fig 3e). Since OSM treatment resulted in a partial increase in the number of p62+ 
puncta compared to bafilomycin treatment, and the combined action of both mediators was 
synergistic, we can deduce that it is more likely that Stat3 activation increases cellular 
autophagic flux rather than blocking the resolution of autophagy. 
 
The inflammatory phenotype of KIM-2 cells is modulated in the presence of macrophages 
when cultures under involution conditions. 
 
Considering the influence of macrophages on glandular development coupled to their 
characteristic influx in the later stages of involution, it is reasonable to propose that their 
presence influences mammary epithelial phenotype. The porous nature of our 3D in vitro 
system is applicable to studies of this type, whereby differing cell types can be introduced to 
established cultures in 3D.  
 
The monocyte/macrophage cell line RAW-264.7 was seeded at 105 cells/mL within a subset 
of 3D KIM2/3T3-L1 cultures, 24hrs prior to the withdrawal of PRL (Fig 4a). This seeding 
density is comparable to macrophage abundance within the mammary gland, although levels 
are variable throughout the estrous cycle36. Macrophages seeded within this in vitro system 
became closely associated with epithelial organoids, visualized by confocal live-cell imaging 
(Fig 4b). This close association of macrophages with alveoli of the lactating gland has been 
previously described, and is dependent on the expression of CSF-115. The addition of a 
stromal component to our model system is advantageous in this respect, since expression of 
CSF-1 and to a lesser extent monocyte chemotactic protein-1 (MCP-1) are transiently up-
regulated over a 12 day 3T3-L1 adipogenic time course (Fig S5a). Re-emmergence of adipose 
tissue is an important feature of involution and it is possible that this pattern of expression 
coincides with the infiltration of macrophages into the gland from 3 days in vivo. In addition, 
PPARγ, a critical adipogenesis regulator is a potent M2 inducible factor37. 
 
We performed an immunohistochemical analysis of the M2/anti-inflammatory marker 
arginase-1 (ARG1) on sections of our involution model (Fig 4c). ARG1/ECAD double 
positive cells increased in frequency with the withdrawal of PRL, indicating that KIM-2 
switch their phenotype from differentiated milk-producing cells to express a marker of the 
M2 anti-inflammatory monocyte/macrophage lineage. Infiltrating macrophages undergo 
conversion to the M2 phenotype within involuting gland in vivo 19 and we confirmed the 
ability of RAW-264.7 cells to M2 conversion prior to co-culture analysis, exploring 
expression of ARG1 and YM-1 coupled to the down-regulation of the M1 marker iNOS under 
10ng/mL IL-4 for 24hrs (Fig S5b). In an earlier study IL-4 cytokine expression was shown to 
be up-regulated by lactogenic KIM2 cells38. Interestingly, in the presence of RAW cells, the 
M2 phenotypic switch in KIM2 cells is negated from 48hrs H/WD onwards (p<0.05) (Fig4,d). 
There is now a consensus that luminal mammary epithelial cells increase their expression of 
phagocytic markers including CD1439 40,19 to allow for the uptake of shed cells and milk 




This paper describes a complex in vitro model of mammary gland generated de novo through 
the combination of essential tissue cell types within 3D engineered scaffolds of natural 
biomaterials. Within the model, organotypic mammary tissues develop and die in a 
physiological manner under the control of lactogenic hormones, demonstrating that such 
models are suitable in vitro platforms for the study of cancer development in which these 
processes are disrupted. Certain limitation of the current model should be highlighted, 
however. Firstly milk stasis through absence of suckling is the initial trigger for LIF induced 
phosphorylation of Stat3 and subsequent involution 41. Three-dimensional models of the type 
presented are static environments where milk is synthesized into a closed system, thereby 
potentially triggering pro-involution conditions spontaneously. Secondly, physiological 
involution within our system can only take place within polar mammary organoids, the 
frequency of which is limited to approximately 70% in 7.5%HA/col scaffolds 1. This residual 
tissue component may complicate signalling microenvironments and data analyses.   
 
Many 3D in vitro models of mammary tissue have been described, however this is the first to 
our knowledge that aims to reflect complex tissue remodelling processes that occur in the 
involuting gland following pregnancy and lactation. The model was used to highlight the role 
of Stat3 signalling in epithelial autophagic processes during the first 96hrs following H/WD, 
mimicked in our mammary involution model. Furthermore, this model demonstrates that 
macrophages present in the latter stages of involution can regulate mammary epithelial 
phenotype, reflecting the power of such models to study cell interactions in defined in vitro 
microenvironments. Models of this type form simple laboratory tools that are amenable to 
scale-up. Furthermore the murine cell lines of the current model could be readily replaced by 
human cell lines, primary cells or tissue biopsy specimens, forming powerful diagnostic 

























Fig 1  3D in vitro culture supports physiological mammary organoid formation. a) 
KIM2 cells were cultured for up to 4 days on 2D plastic or collagen type 1 prepared as thin 
film surfaces or porous freeze dried 3D scaffolds. 3D culture enables expression of 
glycosylated AQP5. b) Schematic of 3D involution model preparation. c) In co-culture with 
differentiated 3T3-L1, KIM2 cells form numerous branched interconnecting ductal and 
epithelial structures (confocal z-stack. bar = 50µm). In transverse section these display polar 
AQP5 towards the luminal cell surface (c, inset bar= 25µm) together with apical tight 
junctions (ZO1) surrounded by basement membrane (Laminin). In the co-culture model 





Fig 2. Morphological analysis of in vitro involution model. a) Hormone withdrawl 
triggered involution results in collapse of lumen structure and disaggregation of organoids 
(bar = 50µm). b) Image analysis of organoids was conducted using image j software, 
manually recording the boundary of organoids with associated lumens (L). d) Organoid 
morphologies described by lumen area, lumen frequency and aspect ratio (AR). AR is a 
function of long axis (l) to short axis ratios calculated from a software applied best-fitting 







Fig 3. 3D model recapitulates in vivo involution phenotype and Stat3 mediated cell death 
mechanisms. a) Immunohistochemical evaluation of KIM-2 mammary organoids during 
H/WD showing MFGE8+ cell shedding into an organoid lumen at 48hrs H/WD. Cleaved 
caspase-3 cells are visible within organoid luminal cavities and epithelial organoid walls 
throughout H/WD as well as p62+ cytoplasmic puncta (bars = 50µm). b) Western analysis of 
involution samples +/- application of OSM. c,d) quantification of cc3 and p62 
immunohistochemical data, proportional to expression in control samples (no PRL 
withdrawal), reveals Stat3 dependent expression of p62 (*= p<0.05, **= p<0.01, #= p <0.05, 
n=5). e) Analysis of autophagic mechanism by application of bafilomycin results in increased 









Fig 4 Macrophage influx model of involution modulates the phenotype of KIM-2 cells. a) 
Schematic of macrophage addition prior to the initiation of involution by H/WD. b) live-cell 
confocal imaging of cell-tracker (red) labelled macrophages associated with GFP labelled 
KIM2 organoids at 24hrs 3D co-culture. Arginase-1 expression in ecad+ KIM2 cells (c) is 




















Supplemental Fig1. KIM-2 cells recapitulate activation of pStat3 in both 2D monoculture (a) 
and 2D trans-well co-culture (b) conditions. Adipose was not found to have an effect on the 
level of pStat3 signalling in the model, although cleaved caspase 3 is more prevalent in the 










































Supplemental Fig 3. Immunohistochemical cc3 quantification in Ecad positive cells at the 
48hr involution timepoint under conditions of H/WD, +/-OSM and pan-caspase OPH 
inhibitor Q-VD (20µM). Additionally caspase was quantified under conditions of serum 

















Supplemental Fig 4. KIM2 cells loaded with Lysotracker ® Red to monitor acidic lysosome 































Supplemental Fig 5. a) CSF-1 and MCP-1 are regulated in 3T3-L1 with adipogenic 






Collagen/hyaluronic acid scaffold and film fabrication 
3D collagen and collagen/HA (7.5 wt%) scaffolds with controlled porosity were fabricated 
using a freeze drying technique with subsequent cross-linking in aqueous 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC) in the presence of N-
hydroxysuccinimide (NHS) as detailed earlier24. Resultant scaffolds were carefully cut into 
discs of 10mm diameter with a 1mm maximum thickness to support nutrient delivery and 3D 
cell seeding. Films of pure collagen were prepared on 60mm tissue culture dishes (Nunc) as 
described previously 1 at the same time as 3D scaffolds and cross-linked in the same manner 
with EDC/NHS before being air-dried. Scaffolds and films were bathed in a 10x solution of 
gentamycin (2.5mg/mL) in phosphate buffered saline (PBS) for 24hrs followed by rinsing 
(x3) in PBS, prior to introduction of cells. 
 
Cell culture and in vitro model preparation. 
3T3-L1 cells (ATCC, Manassas, VA, USA) and KIM-2 cells 42 were maintained as described 
previously. RAW 267.4 cells (a kind gift from Dr. H. Laman, Department of Pathology, 
Cambridge, UK.) were maintained in DMEM (Gibco, Life Technologies, Paisley, UK) + 10% 
FCS (PAA, Som, UK). For a comparison of protein expression in 2D and 3D substrates, 
KIM2 cells were seeded at 3x105 cells/cm2 on plastic or monolayer films and in 3D scaffolds 
at 1x106 cells/mL as described below. For 2D co-cultures, 3T3-L1 were plated at 3x104/cm2 
in 6 well plates and maintained to confluence prior to terminal differentiation with lµM 
dexamethasone (DEX), 0.5 mM 3-iso-butyl-1-methylxanthine (IBMX) and 0.8mM insulin 
(ins) (48hrs) (all Sigma, Poole, UK), and subsequently maintained in DMEM+10%FCS + ins 
for a further week. KIM-2 cells were maintained at confluence on 6 well transwell inserts (0.4 
µm2 pores, Corning, NY, USA) under lacogenic culture conditions (DMEM:F12 + 10% FCS, 
0.8mM ins, 0.2mM PRL, 1mM DEX and 17mM linoleic acid) for 2weeks, prior to co-culture 
with 3T3-L1 under involution conditions. Involution was triggered by removal of PRL from 
lactogenic culture media with and without OSM supplementation (25ng/mL). 3D scaffolds 
were prepared for primary cell seeding by eliminating rinse solution with centrifugation 
(500g) on cell strainers. Compressed scaffolds were then swelled by immersing in 1x106 
cells/mL of either 3T3-L1 or KIM-2 cell suspensions to achieve homogenous 3D seeding. For 
3D co-cultures, pre-seeded scaffolds were carefully blotted prior to the drop-wise addition of 
KIM-2 cells (1x106 cells/mL) or RAW 267.4  (1x105 cells/mL). For 3D involution conditions, 
adipogenesis was initiated as described above for 2weeks, prior to the introduction of KIM-2 
cells. Following 48hrs KIM-2/3T3L1 equilibration, KIM-2 cells were differentiated with 
lactogenic media for 12 days. Involution was induced as described above for a total of 96hrs 
+/- OSM addition. In macrophage influx studies RAW cells were added to 3D cultures 24hrs 
prior to H/WD. Involution control samples (receiving PRL continuously) were taken at both 
0hrs and 96hrs.  
 
Live cell imaging. 
KIM-2 cells transfected with an MSCV-IRES-GFP empty vector (a kind gift from Prof. 
Göttgens, Department of Haematology, Cambridge, UK), were seeded into scaffolds at 1x106 
cell /mL and co-cultured with adipogenic 3T3-L1 in 3D scaffolds as described above. RAW 
267.4 macrophages were loaded with 10 mM cell tracker dye (Celltracker red ® CMTPX, 
Life Technologies) in whole media for 30 minutes prior to seeding in 3D co-culture at 1x105 
cells/mL. Scaffolds were removed to an environment chamber of a confocal microscope 
(Leica TCS SP II, Leica Biosystems, Germany) and analyzed by laser excitation of GFP and 




Immunohistochemistry was carried out on paraffin-embedded sections as described 
previously1. Antibodies (all Cell Signalling Technology, USA, unless otherwise stated) were 
prepared to the following dilutions in 10% sera + PBS + 0.1%Tween20; Ecad (610182, BD 
Biosciences, Oxon, UK, 1/500), ZO-1 (MAB 1570, Millipore, USA, 1/250), AQP5 (AB3559, 
Millipore, 1:200), Laminin (ab11575, Abcam, Cambs, UK, 1:200), Cleaved-caspase 3 (CC3, 
9661S, 1:200). MFGE8 (a kind gift from Prof Nagata, Kyoto University, Japan, 1:200), ARG-
1 (AB91279, Abcam, 1:250), p62 (SQSTM1 MQL, 1:200), Perilipin (D1D8, 1:200). Signal 
was detected using Alexa-488, Cy-3 and Alexa-647 conjugated secondary antibodies (all Life 
Technologies) bisbenzimide-Hoechst 33342 nuclear staining and fluorescence microscopy 
with data capture (Zeiss AxioCam/Axioplan 3, Zeiss, Germany). Immunoblotting and signal 
detection was carried out as previously described (Khaled, 2007) with protein loading 
adjusted by densitometric lane analysis (Quantity One, Biorad, CA, USA) of β-actin 
(Ab8227-50, Abcam) or tubulin (ab6160, Abcam). Antibodies were prepared at the following 
dilutions is tris-buffered saline + 0.1% Tween20; total Stat3 (9132) 1:1000, P-Stat3 (9131) 
1:1000, P-Akt (9271) 1/1000), LC3B (2775) 1:1000, Cathepsin L (MAB9521, R&D systems, 
MN, USA) 1:1000, Cathepsin B (ab33538, Abcam. 1:1000), AQP-5 (1:1000), β-casein (a gift 
from Bert Binas, 1:10000), Ecad (1/2500). Signal was detected using HRP-conjugated 
secondary antibodies (Dako), and ECL, ECL prime (GE healthcare) or Millipore detection 
reagents using manufacturers protocols.  
 
Image analysis and statistics 
Whole organoid and associated lumen morphologies were traced using the freehand selection 
tool in image j software (fig2b). Organoid aspect ratios were calculated by image j, dividing 
long axis (l) and short axis (s) of best fitting ellipse (fig2 c) applied to organoid 
circumferences. All statistical analyses by a priori ANOVA and student T Test were 
performed using Excel data analysis toolpak (Microsoft, CA, USA). 
 
Gene expression analysis. 
Gene expression by PCR was carried out using standard procedures as previously described. 
Validated sequences for the following genes were obtained from Primerbank43 ARG-1 
(7106255a), YM-1, (6753416a1),  inos-2 (6754872a1), PPARγ (6755138a1), CSF-1 
(192801a1), MCP-1 (6755430a1), MMP-11 (6678894a1) and MMP-14 (31982191a1). 
Sequences for Cyclophilin, MMP 2,3 and 9 were validated and published previously 19. All 
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